deltatrials
Terminated PHASE2 NCT00612066

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patient's With Cushing's Disease

Sponsor: Jonsson Comprehensive Cancer Center

Conditions Cushing's Disease
Interventions rosiglitazone maleate
Updated 8 times since 2017 Last updated: Jul 29, 2020 Started: Apr 30, 2007 Primary completion: Nov 30, 2010 Completion: Nov 30, 2010

This PHASE2 trial investigates Cushing's Disease and is currently terminated or withdrawn. Jonsson Comprehensive Cancer Center leads this study, which shows 8 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  5. Sep 2020 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 3 earlier versions

  1. Jun 2018 — Sep 2020 [monthly]

    Terminated PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Jonsson Comprehensive Cancer Center
  • National Institutes of Health (NIH)
Data source: Jonsson Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Los Angeles, United States